Blessing Agunwamba
Memorial Sloan Kettering Cancer Center · 7 works · 4,499 citations · h-index 6
Top works
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel)
- Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).
- The CPEB Protein Orb2 Has Multiple Functions during Spermatogenesis in Drosophila melanogaster
- Melanoma and immunotherapy bridge 2015
- Characterization of the Drosophila CPEB Protein Orb2 in the Germline and Nervous System